Last verified · v1.0

Calculator · health

Easi Score Calculator (Eczema Area And Severity Index)

Calculate EASI eczema severity scores across head, trunk, and limbs with age-adjusted regional weights. Scores range 0-72.

FreeInstantNo signupOpen source

Inputs

Age Group

Head/Neck — Erythema (Redness)

Head/Neck — Induration/Papulation (Thickness)

Head/Neck — Excoriation (Scratching)

Head/Neck — Lichenification

Head/Neck — Area Score

Upper Limbs — Erythema (Redness)

Upper Limbs — Induration/Papulation

Upper Limbs — Excoriation

Upper Limbs — Lichenification

Upper Limbs — Area Score

Trunk — Erythema (Redness)

Trunk — Induration/Papulation

Trunk — Excoriation

Trunk — Lichenification

Trunk — Area Score

Lower Limbs — Erythema (Redness)

Lower Limbs — Induration/Papulation

Lower Limbs — Excoriation

Lower Limbs — Lichenification

Lower Limbs — Area Score

EASI Score

—

Get a plain-English breakdown of your result with practical next steps.

EASI Score—points

The formula

How the
result is
computed.

What Is the EASI Score?

The Eczema Area and Severity Index (EASI) is a validated clinical scoring instrument used to quantify the severity of atopic dermatitis (eczema) across four anatomical body regions. The EASI score ranges from 0 to 72, where higher values indicate greater disease burden. Regulatory agencies including the U.S. Food and Drug Administration designate EASI as a primary endpoint in pivotal atopic dermatitis trials, and it is endorsed by major dermatology societies worldwide as the gold-standard objective measure of eczema severity. An interpretability study published in the British Journal of Dermatology established the widely cited severity banding thresholds used in both clinical practice and research today.

The EASI Formula

The total EASI score sums four regional subscores, each derived from multiplying the combined symptom severity, the area score, and a region-specific body surface area multiplier:

EASI = Σ_{r ∈ {H, U, T, L}} (E_r + I_r + Ex_r + L_r) × A_r × M_r

The four regions are: H = Head/Neck, U = Upper Limbs, T = Trunk (including axillae and groin), and L = Lower Limbs (including buttocks).

Symptom Severity Variables (0–3 each)

E — Erythema (Redness): Intensity of skin redness. 0 = none, 1 = mild, 2 = moderate, 3 = severe.
I — Induration/Papulation (Thickness): Degree of skin thickening or raised papules, scored 0–3.
Ex — Excoriation (Scratch Marks): Visible scratch-induced skin damage, scored 0–3.
L — Lichenification: Chronic skin thickening with exaggerated surface markings from repeated scratching, scored 0–3.

The maximum combined symptom score per region is 12 (four signs × maximum severity of 3).

Area Score (A_r): Discrete 0–6 Scale

The estimated percentage of affected skin within each region converts to a discrete integer:

0 = 0% (no involvement)
1 = 1–9%
2 = 10–29%
3 = 30–49%
4 = 50–69%
5 = 70–89%
6 = 90–100%

Regional Multiplier (M_r): Age-Adjusted Body Surface Area Weighting

Each region carries a multiplier reflecting its proportion of total body surface area. Children under 8 years have a proportionally larger head, requiring adjusted multipliers per the Statistical Analysis Plan specification for EASI in registered AD trials:

Adults (≥8 years): Head/Neck = 0.1 | Upper Limbs = 0.2 | Trunk = 0.3 | Lower Limbs = 0.4
Children (<8 years): Head/Neck = 0.2 | Upper Limbs = 0.2 | Trunk = 0.3 | Lower Limbs = 0.3

EASI Severity Classification

Validated severity bands allow clinicians to communicate disease burden consistently:

0: Clear
0.1–1.0: Almost clear
1.1–7.0: Mild eczema
7.1–21.0: Moderate eczema
21.1–50.0: Severe eczema
50.1–72.0: Very severe eczema

Worked Example (Adult Patient)

An adult with primarily trunk and upper limb involvement might present as follows:

Head/Neck: E=1, I=0, Ex=1, L=0, Area score=1 → (1+0+1+0) × 1 × 0.1 = 0.2
Upper Limbs: E=2, I=1, Ex=2, L=1, Area score=3 → (2+1+2+1) × 3 × 0.2 = 3.6
Trunk: E=2, I=2, Ex=1, L=1, Area score=4 → (2+2+1+1) × 4 × 0.3 = 7.2
Lower Limbs: E=1, I=1, Ex=1, L=0, Area score=2 → (1+1+1+0) × 2 × 0.4 = 2.4

Total EASI = 0.2 + 3.6 + 7.2 + 2.4 = 13.4 — classified as Moderate eczema.

Regulatory and Clinical Significance

The FDA Multidiscipline Review for atopic dermatitis biologics specifies EASI-50, EASI-75, and EASI-90 response thresholds — representing 50%, 75%, and 90% reductions from baseline — as co-primary or key secondary endpoints. The PMC review of digital dermatology severity tools confirms EASI as the preferred objective measure across telemedicine and in-clinic settings alike.

Clinical Application in Dermatology Practice

Dermatologists and atopic dermatitis specialists routinely use EASI scores to track disease progression over time and to objectively document response to therapeutic interventions. The reproducibility of EASI scoring improves substantially with clinician training and standardized photographic documentation protocols; formal training modules are available through major dermatology societies including the American Academy of Dermatology. Baseline EASI assessments at enrollment, follow-up visits at regular intervals, and endpoint measurements form the backbone of modern drug development programs, enabling regulatory agencies to assess therapeutic efficacy with scientific rigor. The dynamic range of the score from 0 to 72 provides sufficient granularity to detect clinically meaningful improvements even in patients with initially mild disease, a characteristic particularly valuable in longitudinal monitoring and in pediatric atopic dermatitis populations where baseline severity may be lower than in adults seeking systemic therapy.

Reference

Frequently asked questions

What is the maximum possible EASI score and what does it mean?

The maximum possible EASI score is 72, reached when all four body regions record the highest symptom severity (12 points each) combined with 100% skin area involvement. In clinical practice, scores above 50 classify as very severe eczema and typically require aggressive systemic therapy or biologic treatment such as dupilumab. Most patients enrolled in moderate-to-severe clinical trials present with baseline EASI scores between 16 and 40.

Why does the EASI calculator require the patient's age group?

The EASI formula uses age-adjusted regional multipliers because children under 8 years have a proportionally larger head and neck relative to total body surface area. For adults aged 8 and older, the head/neck multiplier is 0.1 (representing 10% of BSA), whereas for children under 8 it rises to 0.2 (20%). Correspondingly, the lower limb multiplier decreases from 0.4 in adults to 0.3 in young children. Entering the wrong age group produces a systematically inaccurate total EASI score.

What does an EASI-75 response mean in atopic dermatitis clinical trials?

EASI-75 denotes a 75% reduction in the total EASI score from a patient's baseline value, and it is the most commonly used primary efficacy endpoint in atopic dermatitis registration trials. The FDA and EMA both recognize EASI-75 as a clinically meaningful treatment response threshold. For example, a patient with a baseline EASI of 32 must achieve an EASI score of 8 or below to qualify as an EASI-75 responder. EASI-50 and EASI-90 thresholds (50% and 90% reductions) serve as complementary secondary endpoints in major trials.

How is the area score for each body region determined?

A clinician visually estimates the percentage of skin within each body region showing active eczema, then maps that percentage to a discrete 0-to-6 integer scale: 0 for no involvement, 1 for 1-9%, 2 for 10-29%, 3 for 30-49%, 4 for 50-69%, 5 for 70-89%, and 6 for 90-100%. The trunk region encompasses the axillae and groin, while the lower limbs region includes the buttocks. Accurate area estimation is the most subjective component of the EASI and the principal source of inter-rater variability in clinical settings.

How does EASI differ from SCORAD when assessing eczema severity?

SCORAD integrates patient-reported subjective symptoms (pruritus and sleep disturbance each scored 0-10 on a visual analog scale) alongside objective clinical signs, making it broader but more complex to administer. EASI assesses only objective, physician-observed findings across four body regions and excludes patient-reported outcomes entirely. Clinical trials increasingly favor EASI for its objectivity, reproducibility, and regulatory acceptance, while SCORAD remains valuable in settings where capturing the patient's lived experience of itch and sleep disruption is a primary clinical concern.

Can the EASI score be calculated through remote or teledermatology assessment?

The EASI was originally designed for in-person physician assessment, and accurate scoring traditionally requires hands-on examination to evaluate induration and lichenification. However, as reviewed in the PMC analysis of digital dermatology severity tools, standardized photographic protocols enable remote EASI estimation with acceptable inter-rater agreement for erythema and excoriation. Telemedicine EASI assessments show the greatest variability in the induration and lichenification subscores, which are harder to judge from images. For routine home monitoring between clinic visits, validated patient-reported tools such as the POEM (Patient-Oriented Eczema Measure) offer a more practical alternative.